Floatz logo

N-Acetyl-L-Cysteine

Gaucher Disease Type 1

University of MinnesotaPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Gaucher Disease Type 1 cohort.

Asset / SponsorPhaseRating
Cerezyme
Sanofi
Phase 4A
Velaglucerase Alfa
Baylor Research Institute
Phase 4BB
Cerezyme
Sanofi
Phase 3BB
Eliglustat
Sanofi
Phase 3BB
Miglustat
Actelion
Phase 3BB

View all 13 →

Same molecule, other indications

N-Acetyl-L-Cysteine is also rated in:

idiopathic pulmonary fibrosisDormant
BBB
Indicative ·
74 / 100
View asset →
schizophreniform disorderDormant
BBB
Indicative ·
74 / 100
View asset →
traumatic brain injuryDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →